Company: EDSA
Filing Date: 2025-04-04
Form Type: DEF 14A
Source: 0001171843-25-002028
Chunk: 43

Company: Edesa Biotech, Inc.
Filing Date: 2025-04-04
Form: DEF 14A
Chunk 43
---
4 as follows:

| 1. | The Audit Committee has reviewed and discussed with management the audited financial statements for the Company for the fiscal year ended September 30, 2024.                                                                                                                          |
|:---|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2. | The Audit Committee has discussed with representatives of MNP LLP, the independent public accounting firm, the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board (“PCAOB”) and the SEC.                                 |
| 3. | The Audit Committee has discussed with MNP LLP, the independent public accounting firm, the auditors’ independence from management and the Company has received the written disclosures and the letter from the independent auditors required by applicable requirements of the PCAOB. |

In addition, the Audit Committee considered whether the provision of non-audit services by MNP LLP is compatible with maintaining its independence. In reliance on the reviews and discussions referred to above, the Audit Committee recommended to the Board (and the Board has approved) that the audited financial statements be included in our Annual Report on Form 10-K for the fiscal year ended September 30, 2024 for filing with the SEC.

Audit Committee of Edesa Biotech, Inc.

Joan Chypyha

Patrick Marshall

Carlo Sistilli

___________________________

*The foregoing report of the Audit Committee is not to be deemed “soliciting material” or deemed to be “filed” with the SEC (irrespective of any general incorporation language in any document filed with the SEC) or subject to Regulation 14A of the Securities Exchange Act of 1934, as amended, or to the liabilities of Section 18 of the Securities Exchange Act of 1934, except to the extent we specifically incorporate it by reference into a document filed with the SEC.

<div align='center'>26

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</div>

The following table sets forth certain information with respect to the beneficial ownership of our common shares as of March 31, 2025, by:

| ● | each person (or group of affiliated persons) who is known by us to beneficially own more than 5% of the common shares; |

| ● | each of our named executive officers; |

| ● | each of our directors and director nominee; and |

| ● | all of our directors and current executive officers as a group. |

We have determined beneficial ownership in accordance with SEC rules.